



## RESEARCH ARTICLE

### CORRELATION OF DURATION OF DIABETES MELLITUS AND SEX SPECIFIC DISTRIBUTION AS A RISK FACTOR FOR PROGNOSIS OF COVID-19

Dr. Dhananjay Bhale<sup>1</sup>, Dr. Ruta Anandgaonkar<sup>1</sup> and Mr. Vaibhav Deshmukh<sup>2</sup>

<sup>1</sup>Professor of Biochemistry and Ex Head of Department, MGM Medical College, Chh. Sambhajinagar, India; <sup>1</sup>Assistant Professor of Biochemistry, MGM Medical College, Chh. Sambhajinagar, India; <sup>2</sup>PG student Department, MGM Medical College, Chh. Sambhajinagar, India

#### ARTICLE INFO

##### Article History:

Received 09<sup>th</sup> March, 2025  
Received in revised form  
21<sup>st</sup> April, 2025  
Accepted 19<sup>th</sup> May, 2025  
Published online 24<sup>th</sup> June, 2025

##### Key words:

Naphthalimide,  
Al<sup>3+</sup>, Fluorescent Probe.

##### \*Corresponding author:

Dr. Dhananjay Bhale

#### ABSTRACT

To know whether duration of diabetes is a risk factor influencing the progression and prognosis of novel coronavirus disease (COVID-19). Material and Methods: A total 96 consecutive patients confirmed with COVID-19 with diabetes mellitus were studied in MGM Medical College and Hospital. Demographic data, medical history, symptoms and signs, laboratory findings, chest computed tomography (CT) as well the treatment measures were collected and analysed. Results: We found that majority of cases with COVID-19 and diabetes mellitus were more between age group of 31 to 40 (n = 29). Male to female ratio was 1.5:1. Patients having duration of Diabetes mellitus of more than 10 years were having bad prognosis. (1% Surived). These patients were at higher risk of severe pneumonia, release of tissue injury related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism. Furthermore, serum levels of inflammation-related biomarker such as D-dimer, were significantly higher (P < .01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of COVID-19. Conclusions: Our data supports the notion that duration of diabetes mellitus and sex specific distribution should be considered as a risk factor for a rapid progression and bad prognosis of COVID-19. More intensive attention should be paid to male patients with diabetes mellitus with long duration and having COVID-19

Copyright©2025, Dhananjay Bhale et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Dr. Dhananjay Bhale, Dr. Ruta Anandgaonkar and Mr. Vaibhav Deshmukh. 2025. "Correlation of Duration of Diabetes mellitus and sex specific distribution as a risk factor for prognosis of COVID-19.". *International Journal of Current Research*, 17, (06), 33304-33307.

## INTRODUCTION

Diabetes mellitus is one of the leading causes of morbidity worldwide and is anticipated to rise substantially over the next decades (1). Several investigations have demonstrated a higher susceptibility to some infectious diseases in diabetic people, like Staphylococcus aureus and Mycobacterium tuberculosis (2-4) probably owing to the dysregulated immune system (5). It has reported that plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS.(6)A retrospective study in Wuhan, China revealed that of the 41 COVID-19 patients, 32% of them had underlying diseases, and among which 20% was diabetes (7). Therefore, these diabetic patients might be at increased risk of COVID-19 and have a poorer prognosis.

**Aims and objectives:** To know whether diabetes is a risk factor to influence the progression and prognosis of COVID-19.

## MATERIALS AND METHODS

96 COVID-19 patients who were admitted to MGM Medical college and Hospital from September 2022 to February 2024 were included in this study according to the inclusion criteria. Their basic information, laboratory examinations were collected and analysed. The present study was conducted in Department of biochemistry and central investigation laboratory at MGM Medical college and hospital Aurangabad. The study was approved by Institutional Ethical and Research committee to use patients blood in the research study.

#### INCLUSION CRITERIA:

Patients more than 18 years old. All Samples from SARS(Severe acute respiratory syndrome) COVID-19 Infected Patient with Diabetes mellitus disorder.


**EXCLUSION CRITERIA:** <18 years age excluded

**OBSERVATION AND RESULTS**

**Table1. Distribution of cases according to age in DM with COVID-19**

| Sr No | Age    | Number of cases N | Percentage% |
|-------|--------|-------------------|-------------|
| 1     | 18to20 | 11                | 11 %        |
| 2     | 21to30 | 12                | 13 %        |
| 3     | 31to40 | 29                | 30 %        |
| 4     | 41to50 | 18                | 19 %        |
| 5     | >50    | 26                | 27 %        |
| Total |        | 96                | 100 %       |


As shown Table 1, majority cases were between 31to 40 years i.e.29 (30%) cases followed by 26 (27 %) in age >50 years.



**Graph 1 Majority cases were between 31to 40 years i.e.29 (30%) cases followed by 26 (27 %) in age >50 years.**

| Sr No | Gender | Number of cases N | Percentage% |
|-------|--------|-------------------|-------------|
| 1     | Male   | 58                | 60 %        |
| 2     | Female | 38                | 40 %        |
| Total |        | 96                | 100 %       |

As shown Table 2, male cases were 58 (60%) and female cases were 38(40%). Male to female ratio was 1.5:1 (Graph 2)




**Graph 2. Showing Distribution of cases according to Gender in DM with COVID-19**

**Table 3. Distribution of cases according to Duration of Diabetes Mellitus with COVID-19**

| Sr No | Duration of diabetes (Years) | Number of cases N | Percentage % |
|-------|------------------------------|-------------------|--------------|
| 1     | ≤10                          | 54                | 56 %         |
| 2     | >10                          | 42                | 44 %         |
| Total |                              | 96                | 100 %        |

As shown Table 3, Duration of diabetes (Years) was ≤10 in 54(56%) cases and 10 years in 42.(44 %)(Graph 1)




**Graph 3. Showing Duration of diabetes (Years) was ≤10 in 54(56%) cases and 10 years in 42.(44 %)(Graph 3) (27%) cases of > 50years (Graph1)**

**Table 4. Correlation of Duration of diabetes & Prognosis in DM with COVID-19**

| Sr No | Duration of Diabetes (Years) | Survived N (%) | Not Survived N (%) | Total N (%) | Chi Square | P value          |
|-------|------------------------------|----------------|--------------------|-------------|------------|------------------|
| 1     | ≤10                          | 93(97%)        | 1(1%)              | 94(98%)     | 41.74      | < 0.0000<br>1(S) |
| 2     | >10                          | 1(1%)          | 1(1%)              | 2(2%)       |            |                  |
| Total |                              | 94(98%)        | 2(2%)              | 96(100%)    | -          | -                |

As shown in Table 4, amongst 94 (98 %) cases who had Duration of diabetes ≤10, 93(98%) Survived whereas amongst 2(2%) cases who had Duration of diabetes>10,1(1%) Survived. Result showed statistically significant correlation between duration of diabetes & prognosis(P<0.00001).(Graph 4)



**Graph 4. Correlation of Duration of diabetes & Prognosis in DM with COVID-19**

**Table 5. Distribution of cases according to Prognosis in DM with COVID-19**

| Sr No | Prognosis    | Number of cases N | Percentage % |
|-------|--------------|-------------------|--------------|
| 1     | Survived     | 94                | 98 %         |
| 2     | Not survived | 2                 | 2 %          |
| Total |              | 96                | 100 %        |

**Table 6. Distribution of cases according to Blood sugar profile in DM with COVID 19**

| Sr No | Blood sugar profile      | Mean   | SD    |
|-------|--------------------------|--------|-------|
| 1     | Fasting blood sugar      | 150.70 | 18.21 |
| 2     | Postprandial blood sugar | 311.50 | 47.05 |

## DISCUSSION

Diabetes, a major metabolic disorder, is one of the leading causes of mortality and morbidity throughout the world (8). Several studies have shown that diabetics infected with Influenza A (H1N1), MERS-CoV, and SARS-CoV exhibit severe disease symptoms and succumb to death compared to non-diabetic individuals (9,10,11). Similarly, infection with SARS-CoV-2 is also associated with severe complications in diabetics. For example, SARS-CoV-2 infection led to the release of unusually high glucocorticoids and catecholamines, which further elevated blood glucose (12). The hyperglycemic condition, in turn, recruits the pro-inflammatory monocytes, enhances platelet reactivity, and therefore contributes to increases in the number of cardiovascular deaths in diabetic individuals (13). COVID-19 is a disease caused by a SARS-CoV-19 virus. It can be very contagious and spreads quickly. Over one million people have died from COVID-19 in the United States of America. Diabetes Mellitus is considered one of the major comorbidities encountered in severe forms of COVID-19. Many reports showed that the prevalence of DM was nearly 10%, and his incidence in severe cases was about twofold that of non-severe patients. D-dimer is a marker of fibrin and fibrinolysis turnover, with unique molecular properties to work as a biological marker for haematological abnormalities (clotting disorder). Hyperglycaemia in diabetes is thought to cause dysfunction of the immune response, in many ways such as altering macrophages functions and deregulating neutrophil synthesis, which may lead to failure to control the spread of pathogens in diabetic Mellitus subjects. Therefore, Diabetic subjects are known to be more susceptible to infections. (14) With this background we have conducted present study in 96 diabetes mellitus patient with covid-19 disease. Role of D-dimer, fasting blood glucose level (FBG), Post prandial blood sugar level (PPSL) were evaluated in all the patient and result in Diabetes Mellitus patient with covid-19 disease.

**Age distribution:** In present study As shown Table 1, majority cases were between 31 to 40 years i.e. 29 (30%) cases followed by 26 (27%) cases of > 50 years. (Graph 1) In similar study by Dipesh Karki, Iroshani Gurung, number of cases found as age 20 to 39-13%, 40 to 59-37%, 60 and above 35%. (15). In similar study by Lilith Fauchaux, number of cases were found as age >50 is 29%. (16)

**Gender distribution:** In present study As shown Table 2, male cases were 58(60%) and female cases were 38(40%). Male to female ratio was 1.5:1. (Graph 2). In similar study by Hannah M. Nemeč, MD, Allison Ferenczy, according to gender distribution was male N=46 C female N=51. (17). In similar study by Farideh A. Javid I\*, Fadi Abdul Waheed I, according to gender distribution was male N=251 C female N=344. (18). In similar study by Noha M. Elemam, B. Pharma, PhD, according to gender distribution was male N=170 C female N=69. (19)

**Duration of diabetes distribution:** As shown Table 3, Duration of diabetes (Years) was  $\leq 10$  in 54 (56%) cases and >10 years in

42 (44%). (Graph 3) In similar study by Muhammed Kernalia, Raveena Kaur Khalsaa duration of Diabetes was  $\leq 15$  years in 166(60%) cases and >15 years in 111(40%). (20).

**Distribution of cases according to Blood sugar profile:** In Present Study As shown Table 6, Fasting blood sugar mean  $\pm$  SD was 150.70  $\pm$  18.21 and Postprandial blood sugar mean  $\pm$  SD was 311  $\pm$  47.05 (Graph 4). In similar study by Weijia Xie, Na Wua Bin Wang Fasting blood sugar mean  $\pm$  SD was 177.70  $\pm$  24.20 and Postprandial blood sugar mean  $\pm$  SD was 341  $\pm$  59.04. (21) In similar study by Nirmala Devi Chandrasekaran and Thirunavukkarasu Sathish, Fasting blood sugar mean  $\pm$  SD was 136.20  $\pm$  16.50 and Postprandial blood sugar mean  $\pm$  SD was 280  $\pm$  42.08. (22)

**Distribution of cases according to Prognosis:** In present study As shown Table 4 and 5, 94(98%) cases had survived at the time of discharge. (Graph 4) In similar study by Md. Shahed Morshed, Abdullah Al Mosabbir 869 out of 925 (94%) case had survived at the time of discharge. (23). In present study by Jennifer E. Nyland, Nazia T. Raja-Khan, Kerstin Bettermann, 28630 (97%) out of 29516 covid-19 patient with diabetes mellitus had survived at the time of discharge. (24)

## REFERENCES

- Knapp S. Diabetes and infection: is there a link?—a mini-review. *Gerontology*. 2013;59(2):99-104.
- Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. *Diabetes Care*. 2003;26(2):510-513.
- Muller LM, Gorter KJ, Hak E, *et al*. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clin Infect Dis*. 2005;41(3):281-288.
- Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. *N Engl J Med*. 1999;341(25):1906-1912.
- Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. *Immunology*. 2015;144(2):171-185.
- Yang JK, Feng Y, Yuan MY, *et al*. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. *Diabetic Med*. 2006;23(6):623-628.
- Wang D, Hu B, Hu C, *et al*. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323:1061.
- Skyler J.S. Diabetes mellitus: Pathogenesis and treatment strategies. *J. Med. Chem*. 2004;47:4113-4117. doi: 10.1021/jm0306273. (DOI) (PubMed) (Google Scholar)
- Singh A.K., Khunti K. Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: A narrative review. *Diabetes Res. Clin. Pract*. 2020;165:108266. doi: 10.1016/j.diabres.2020.108266. (DOI) (PMC free article) (PubMed) (Google Scholar)
- Al-Sayyar A., Hulme K.D., Thibaut R., Bayry J., Sheedy F.J., Short K.R., Alzaid F. Respiratory Tract Infections in Diabetes—Lessons from Tuberculosis and Influenza to Guide Understanding of COVID-19 Severity. *Front. Endocrinol*. 2022;13:919223. doi: 10.3389/fendo.2022.919223. (DOI) (PMC free article) (PubMed) (Google Scholar)
- Mazucanti C.H., Egan J.M. SARS-CoV-2 disease severity and diabetes: Why the connection and what is to be done? *Immun. Ageing*. 2020;17:21. doi: 10.1186/s12979-020-00192-y. (DOI) (PMC free article) (PubMed) (Google Scholar)
- Wang A., Zhao W., Xu Z., Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. *Diabetes Res. Clin. Pract*.

- 2020;162:108118. doi: 10.1016/j.diabres.2020.108118. (DOI) (PMC free article) (PubMed) (Google Scholar)
13. Hussain A., Bhowmik B., do Vale Moreira N.C. COVID-19 and diabetes: Knowledge in progress. *Diabetes Res. Clin. Pract.* 2020;162:108142. doi: 10.1016/j.diabres.2020.108142. (DOI) (PMC free article) (PubMed) (Google Scholar)
  14. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type2 diabetes and its impact on the immune system. *Curr Diabetes Rev.* 2020;16(5):442-449.
  15. Dipesh Karki, 1Roshani Gurung, Raised D-dimer among Admitted COVID-19 Patients in a Tertiary Care Centre: A Descriptive Cross-sectional Study: *J Nepal Med Assoc* 2022;60(251):596-9.
  16. Lilith Faucheux: Comparison of characteristics and laboratory tests of COVID-19 hematological patients from France and Brazil During the pre-vaccination period: identification of Prognostic profiles for survival: *hematol transfuse cellther.* 2023;45(3):306–316.
  17. Hannah M. Nemece, MD1, Allison Ferenczy: Correlation of D-dimer and Outcomes in COVID-19 Patients: *The American Surgeon* 2022, Vol. 88(9) 2115–2118 © The Author(s) 2022
  18. Farideh A. Javid1\*, Fadi Abdul Waheed1 : COVID-19 and diabetes in 2020: a systematic Review: Javid et al. *Journal of Pharmaceutical Policy and Practice*(2023)16:42 <https://doi.org/10.1186/s40545-023-00546-z>.
  19. Noha M. Elemam, B. Pharma, Diabetes mellitus as a comorbidity in COVID-19 Infection in the United Arab Emirates: *Saudi Med J* 2021;Vol.42(2).
  20. Ceriello A. Hyperglycemia and COVID-19: what was known and what is really New? *Diabetes Res Clin Pract* 2020; 167:108383.
  21. Weijia Xiea, 1NaWua: Bin Wang Fasting plasma glucose and glucose fluctuation are associated with COVID-19 prognosis regardless of pre-existing: *diabetes research and clinical practice* 180(2021)109041.
  22. Nirmala Devi Chandrasekar anand Thirunavukkarasu Sathish: Glycemia and New-Onset Diabetes among COVID-19 Patients with Prediabetes: A Follow-Study of Case Series in India: *Diabetology* 2023,4,19–27. <https://doi.org/10.3390/diabetology4010003>.
  23. Md. Shahed Morshed, Abdullah Al Mosabbir : Comparing between survived and deceased patients with Diabetes Mellitus and COVID-19 in Bangladesh: A sectional study from a COVID-19 edicated hospital med Rxiv preprint doi: <https://doi.org/10.1101/2021.04.04.21254884>;
  24. Jennifer E. Nyland, Nazia T. Raja-Khan, Kerstin Bettermann: Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study : *Diabetes* 2021;70:2903–2916 <https://doi.org/10.2337/db21-0385>.

\*\*\*\*\*